Specify a stock or a cryptocurrency in the search bar to get a summary
ImmunoCellular Therapeutics Ltd
IMUCImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Address: 136 Summit Avenue, Montvale, NJ, United States, 07645
Analytics
WallStreet Target Price
5 USDP/E ratio
0.018Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IMUC
Dividend Analytics IMUC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMUC
Stock Valuation IMUC
Financials IMUC
Results | 2019 | Dynamics |